An anatomical rendering of a red heart
The new AHRQ grant is the latest accolade for Keim-Malpass, who is refining the use of predictive software's role in the care of acutely ill heart patients.

Associate professor Jessica Keim-Malpass has earned a $1.2 million R01 grant from the Agency for Research and Quality (AHRQ) to continue her work to assess and integrate predictive monitoring software into hospital intensive care units to inform the care of acutely ill patents suffering from cardiological problems.


Keim-Malpass's new three-year AHRQ grant

The new three-year AHRQ grant—"Predictive monitoring: IMPact of real-time predictive monitoring in acute care cardiology trial (PM-IMPACCT)"—supports Keim-Malpass's randomized controlled trial that will evaluate the impact of predictive analytics monitoring on improvement in patient outcomes, response time to proactive clinical action, and costs to the healthcare system.

Keim-Malpass's team includes UVA School of Medicine colleague Jamie Bourque as well as UVA public health scientists Sarah Ratcliffe and Tanya Wancheck.

Keim-Malpass—also a National Academy of Medicine Scholar in Diagnostic Excellence, a Betty Irene Moore Fellow, and a Costs of Care Fellow alumna. who has also earned funding from the National Science Foundation and the National Institutes of Health, among other organizations—studies the use and deployment of predictive analytics in acutely ill and vulnerable patient populations, healthcare economics, and health policy.

A pediatric nurse practitioner and a professor of pediatrics in UVA's School of Medicine, the work is a continuation and expansion of an effort she first undertook with UVA cardiologist Randall Moorman on the novel CoMET software, which uses continuous monitoring to assess COVID patients' trajectories and create an image of risk and future decompensation.

Keim-Malpass and her team expect to have preliminary results this November/December.